Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

Bristol-Myers Squibb and Otsuka have introduced two new formulations of their antipsychotic medication Abilify in the USA, to make it easier for doctors to dose patients effectively. Bristol-Myers ...

Co confirmed that it has initiated a challenge of the patent listed by Otsuka Pharmaceutical Co., Ltd in connection with its Abilify (aripiprazole) tablets, 2mg, 5mg, 10mg, 15mg, 20mg & 30mg.

Hello Dr Yesterday I went for a D&C after my unborn baby's heart stopped beating at 9 weeks. Last year at the end of October my water broke at 20 weeks and I lost the baby at 22 weeks. I have one ...